Thyroid News and Research RSS Feed - Thyroid News and Research

New research sheds light on outcomes for patients with thyroid cancer

New research sheds light on outcomes for patients with thyroid cancer

Thyroid cancer survivors report poor quality of life after diagnosis and treatment compared with other patients who are diagnosed with more lethal cancers, according to new research from the University of Chicago Medicine. [More]
Advanced thyroid cancer rates above national average in several parts of California

Advanced thyroid cancer rates above national average in several parts of California

A team of UCLA researchers found that there are several parts of California where, in a high percentage of people with thyroid cancer, the disease is already at an advanced stage by the time it is diagnosed. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Progesterone supplements fail to improve birth rate among women with a history of miscarriage

Progesterone supplements fail to improve birth rate among women with a history of miscarriage

A new study has shown that taking progesterone supplements during the first trimester of pregnancy does not improve the chances of maintaining pregnancy among women who have a history of unexplained recurrent miscarriage. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. [More]
Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients. [More]
Study highlights possible inaccuracies in thyroid cancer detection tests

Study highlights possible inaccuracies in thyroid cancer detection tests

Protein biomarkers are used to test for cancer before and after surgeries to remove tumors. To test thyroid malignancy, many biomarkers are tested separately to confirm cancer. However, new research from Michigan Technological University shows that the detection tests that measure two major biomarkers to diagnose thyroid cancer may be inaccurate. [More]
Eight myths and truths about Alzheimer's disease

Eight myths and truths about Alzheimer's disease

Although Alzheimer's disease (AD) impacts more than five million Americans and 15 million caregivers year-round, the nation is especially focused on the disease this month as it observes "National Alzheimer's Disease and Awareness Month." [More]
AACR rapid and dramatic responses in TRK fusion patients

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. [More]
Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States. [More]
Gastric reduction surgery can significantly increase patient's risk of developing allergy

Gastric reduction surgery can significantly increase patient's risk of developing allergy

Amongst other things, operations to reduce the size of the stomach can significantly increase the patient's risk of developing an allergy. This is the conclusion of a study conducted by the Medical University of Vienna. [More]
Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture. [More]
Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. [More]
Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. [More]
Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

Discovery may lead to development of cell-based regenerative therapy to restore thyroid function

A discovery made by investigators from Beth Israel Deaconess Medical Center and the Boston University School of Medicine may help lead to the development of a cell-based regenerative therapy which could be used to restore thyroid function in patients with cancer who have had their thyroids surgically removed and children born with congenital hypothyroidism. [More]
Nagoya University professor receives 2015 Van Meter Award for thyroid research

Nagoya University professor receives 2015 Van Meter Award for thyroid research

Takashi Yoshimura, a professor at the Institute of Transformative Bio-Molecules at Nagoya University in Japan, has won the 2015 Van Meter Award for his contributions to thyroid research. [More]
Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery. [More]
Latest research on thyroid cancer to be highlighted at 15th International Thyroid Congress

Latest research on thyroid cancer to be highlighted at 15th International Thyroid Congress

The effect of radiation exposure related to the nuclear accidents that took place in Fukushima, Japan, and Chernobyl, Ukraine on thyroid cancer risk, whether dietary habits influence the risk of developing thyroid cancer, and recent study results with a triiodothyronine (T3) analog in an uncommon form of thyroid disease are all topics featured in oral presentations delivered at the 15th International Thyroid Congress, hosted by the American Thyroid Association, October 18-23, 2015, in Orlando, Florida. [More]

New ATA guidelines for managing adult patients with thyroid nodules and DTC published in Thyroid journal

New, evidence-based recommendations from the American Thyroid Association will help guide clinicians in managing patients with thyroid nodules, a common disorder that requires evaluation to distinguish benign nodules from malignancy, interpret biopsy results and molecular marker studies, and initiate risk assessment and cancer screening. [More]
Advertisement